

10/527500

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	4239-66903-02
	Application Number	Not yet assigned
	Filed	Herewith
	First Named Inventor	Valenzuela
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
/NA/		BARRAL <i>et al.</i> , "Human immune response to sand fly salivary gland products is a useful epidemiological marker," <i>Am. J. Trop. Med. Hyg.</i> 62:740-745, 2000
		BELKAID <i>et al.</i> , "Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis," <i>J Exp Med</i> 188, 1941-1953, 1998
		BELKAID <i>et al.</i> , "Delayed-type hypersensitivity to Phlebotomus papatasi sand fly bite: An adaptive response induced by the fly?" <i>Proc Natl Acad Sci U S A</i> 97, 6704-6709, 2000
		CAMPBELL, <i>Monoclonal Antibody Technology</i> . New York: Elsevier Science Publishing Co., Inc., pages 1-32, 1984
		SAMBROOK <i>et al.</i> , eds., <i>Molecular Cloning: A Laboratory Manual</i> , 2 <sup>nd</sup> edition. Cold Spring Harbor Laboratory Press, Vol. 3, pages 16.2 - 16.81, 1989
		TITUS <i>et al.</i> , "Salivary gland lysates of the sand fly <i>Lutzomyia longipalpis</i> enhance <i>Leishmania</i> infectivity," <i>Science</i> 239(4845):1306-1308, 1988
		VALENZUELA <i>et al.</i> , "Toward a defined anti- <i>Leishmania</i> vaccine targeting vector antigens: Characterization of a protective salivary protein," <i>J. Exp. Med.</i> 194:331-342, 2001
		Database A_Genseq_29June04 Accession No. ABB71995, 26 March 2002, 1 page
		Database A_Genseq_29June04 Accession No. ABG718028, 18 Feb 2002, 1 page
		Database SPTreMBL Accession No. Q95WD8, 19 Dec 2001, 6 pages
		Database SPTreMBL Accession No. Q23404, 6 June 1998, 5 pages
		Database A_Genseq_29June04 Accession No. AAG03191, 6 Oct 2000, 1 page
		Database A_Genseq_29June04 Accession No. ABG24332, 18 Feb 2002, 1 page
↓		Database SPTreMBL Accession No. Q9HNC7 16 March 2001, 4 pages

EXAMINER SIGNATURE: /Nina Archie/	DATE CONSIDERED: 09/26/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

DT15 Rec'd PCT/PTO , 1 1 MAR 2005

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	4239-66903-02
		Application Number	Not yet assigned
		Filed	Herewith
		First Named Inventor	Valenzuela
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
/NA/		Database A_Genseq_29June04 Accession No. AAU48010, 27 Feb 2002, 1 page	
		Database SPTreMBL Accession No. Q95WE2, 1 Dec 2001, 1 page	
		Database PIR_78 Accession No. G81431, 31 March 2000, 2 pages	
		Database SPTreMBL Accession No. Q9XZ44, 12 Nov 1999, 4 pages	
		Database A_Genseq_29June04 Accession No. AAB94843 26 June 2001, 1 page	
		Database A_Genseq_29June04 Accession No. ABB61398, 26 March 2002, 1 page	
		Database A_Genseq_29June04 Accession No. AAB42952, 08 Feb 2001, 1 page	
		Database SPTreMBL Accession No. Q9RVD4, 1 May 2000, 1 page	
		Database SPTreMBL Accession No. Q95WE2, 1 Dec 2001, 2 pages	
		Database PIR_78 Accession No. B64020, 10 Sep 1999, 1 page	
		Database A_Genseq_29June04 Accession No. ABB57882, 26 March 2002, 1 page	
		Database PIR_78 Accession No. T50116, 9 June 2000, 1 page	
		Database PIR_78 Accession No. F90270, 24 May 2001, 1 page	
		Database A_Genseq_29June04 Accession No. ABB58845, 26 March 2002, 1 page	
		Database A_Genseq_29June04 Accession No. AAB83185, 9 July 2001, 1 page	
		Database Swissprot_42 Accession No. Q57124, 10 Nov 1997, 1 page	

EXAMINER  
SIGNATURE:

/Nina Archie/

DATE

CONSIDERED:

09/26/2007

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

7/1/05

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	4239-66903-02
	Application Number	10/527,500
	Filing Date	March 11, 2005
	First Named Inventor	Valenzuela
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/NA/		WIPO/PCT	WO 95/06729	9 March 1995	Matlashewski <i>et al.</i>
/NA/		WIPO/PCT	WO 02/102324	27 Dec 2002	Valenzuela <i>et al.</i>
/NA/		WIPO/PCT	WO 2004/039958	13 May 2004	Valenzuela <i>et al.</i>

**OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
/NA/		ADLER <i>et al.</i> , "The mouthparts, alimentary tract and salivary apparatus of the female <i>Phlebotomus papatasi</i> ," <i>Ann. Trop. Med. Parasitol.</i> 20:109, 1926.
↓		BELKAID <i>et al.</i> , "A natural model of <i>Leishmania major</i> infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity," <i>J. Immunol.</i> 165:969-977, 2000.
↓		CHARLAB <i>et al.</i> , "Toward an understanding of the biochemical and pharmacological complexity of the saliva of a hematophagous sand fly <i>Lutzomyia longipalpis</i> ," <i>Proc. Natl. Acad. Sci., USA.</i> 96(26):15155-15160, 1999
↓		HASKÓ <i>et al.</i> , "Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice," <i>J. Immunol.</i> , 157(10):4634-4640, 1996
↓		HASKÓ <i>et al.</i> , "Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms," <i>FASEB J.</i> , 14(13):2065-2074, 2000
↓		GURUNATHAN <i>et al.</i> , "Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with <i>Leishmania major</i> ," <i>J. Exp. Med.</i> 186:1137-1147, 1997.
↓		GURUNATHAN <i>et al.</i> , "Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection," <i>Nat. Med.</i> 4:1409-1415, 1998.
↓		KAMHAWI <i>et al.</i> , "Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies," <i>Science</i> 290:1351-1354, 2000.
↓		KATZ <i>et al.</i> , "Adenosine, AMP, and protein phosphatase activity in sand fly saliva," <i>Am. J. Trop. Med. Hyg.</i> 62:145-150, 2000.

EXAMINER SIGNATURE: /Nina Archie/	DATE CONSIDERED: 09/26/2007
-----------------------------------	-----------------------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.


<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	4239-66903-02
		Application Number	10/527,500
		Filing Date	March 11, 2005
		First Named Inventor	Valenzuela
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS	
/NA/		KILLICK-KENDRICK, Biology of <i>Leishmania</i> in phlebotomine sand flies. In Biology of the Kinetoplastida. W. Lumsden and D. Evans, editors. Academic Press, New York. 395, 1979	
		LERNER <i>et al.</i> , "Isolation of maxadilan, a potent vasodilatory peptide from the salivary glands of the sand fly <i>Lutzomyia longipalpis</i> ," <i>J. Biol. Chem.</i> , 266(17):11234-11236, 1991	
		MAKOUL <i>et al.</i> , "Prostaglandin E2 inhibits the activation of cloned T cell hybridomas," <i>J. Immunol.</i> , 134(4):2645-2650, 1985	
		MELLANBY, "Man's Reaction to Mosquito Bites," <i>Nature</i> 158(4016):554-555, 1946	
		MÉNDEZ <i>et al.</i> , "The potency and durability of DNA- and protein-based vaccines against <i>Leishmania major</i> evaluated using low dose, intradermal challenge," <i>J. Immunol.</i> 166(8):5122-5128, 2001.	
		MODI <i>et al.</i> , "A simple technique for mass rearing <i>Lutzomyia longipalpis</i> and <i>Phlebotomus papatasi</i> (Diptera: Psychodidae) in the laboratory," <i>J. Med. Ent.</i> 20:568-569, 1983.	
		NONG <i>et al.</i> , "Peptides encoded by the calcitonin gene inhibit macrophage function," <i>J. Immunol.</i> , 143(1):45-49, 1989	
		QURESHI <i>et al.</i> , "Immunomodulatory properties of maxadilan, the vasodilator peptide from sand fly salivary gland extracts," <i>Am. J. Trop. Med. Hyg.</i> , 54(6):665-671, 1996	
		RIBEIRO <i>et al.</i> , "Blood-finding strategy of a capillary-feeding sandfly, <i>Lutzomyia longipalpis</i> ," <i>Comp. Biochem. Physiol.</i> , 83(4):683-686, 1986	
		RIBEIRO <i>et al.</i> , "Salivary apyrase activity of some Old World phlebotomine sand flies," <i>Insect Biochem.</i> 19:409-412, 1989.	
		RIBEIRO <i>et al.</i> , "Salivary glands of the sand fly <i>Phlebotomus papatasi</i> contain pharmacologically active amounts of adenosine and 5'-AMP," <i>J. Exp. Biol.</i> , 202(Pt. 11):1551-1559, 1999	
		SANTOLI <i>et al.</i> , "Prostaglandin E precursor fatty acids inhibit human IL-2 production by a prostaglandin E-independent mechanism," and Zurier, <i>J. Immunol.</i> , 143(4):1303-1309, 1989	
		SJÖLANDER <i>et al.</i> , "Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis," <i>J. Immunol.</i> 160:3949-3957, 1998.	
EXAMINER SIGNATURE:		/Nina Archie/	DATE CONSIDERED: 09/26/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	4239-66903-02
		Application Number	10/527,500
		Filing Date	March 11, 2005
		First Named Inventor	Valenzuela
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Examiner's Initials*	Cite No. (optional)	<b>OTHER DOCUMENTS</b>	
/NA/		SMELT <i>et al.</i> , "B cell-deficient mice are highly resistant to <i>Leishmania donovani</i> infection, but develop neutrophil-mediated tissue pathology," <i>J. Immunol.</i> 164:3681-3688, 2000.	
↓		SOARES <i>et al.</i> , "The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor," <i>J. Immunol.</i> 160:1811-1816, 1998	
		STOCKMAN <i>et al.</i> , "The effect of prostaglandins on the in vitro blastogenic response of human peripheral blood lymphocytes," <i>Exp. Hematol.</i> , 2(2):65-72, 1974	
		THEODOS <i>et al.</i> , "Analysis of enhancing effect of sand fly saliva on <i>Leishmania</i> infection in mice," <i>Infect. Immun.</i> 59:1592-1598, 1991.	
		TITUS <i>et al.</i> , "The role of vector saliva in transmission of arthropod-borne disease," <i>Parasitology Today</i> 6(5):157-160, 1990.	
		VALENZUELA <i>et al.</i> , "The salivary apyrase of the blood-sucking sand fly <i>Phlebotomus papatasi</i> belongs to the novel Cimex family of apyrases," <i>J. Experimental Biology</i> , 204:229-237, 2001.	
		WEBSTER, "Role of purines in lymphocyte function," <i>Asian Pac. J. Allergy Immunol.</i> , 2(2):311-317, 1984	
	↓		XU <i>et al.</i> , "Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of <i>L. major</i> ," <i>Immunology</i> 84:173-176, 1995.

EXAMINER SIGNATURE:	/Nina Archie/	DATE CONSIDERED:	09/26/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Attorney Docket Number</b>	4239-66903-02
		<b>Application Number</b>	10/527,500
		<b>Filing Date</b>	March 11, 2005
		<b>First Named Inventor</b>	Valenzuela
		<b>Art Unit</b>	
		<b>Examiner Name</b>	
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>	
/NA/		Killick-Kendrick <i>et al.</i> , "Mark-release-recapture of sand flies fed on leishmanial dogs: the natural life-cycle of <i>Leishmania infantum</i> in <i>Phlebotomus ariasi</i> ," <i>Parassitologia</i> , 44(1-2):67-71, 2002.	
/NA/		Supplementary Partial European Search Report issued on November 30, 2005, for European Patent Application No. 03759395.1.	

<b>EXAMINER SIGNATURE:</b>	/Nina Archie/	<b>DATE CONSIDERED:</b>	09/26/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			



**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

<b>Attorney Docket Number</b>	4239-66903-02
<b>Application Number</b>	10/527,500
<b>Filing Date</b>	March 11, 2005
<b>First Named Inventor</b>	Valenzuela
<b>Art Unit</b>	
<b>Examiner Name</b>	

<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>
/NA/		VOLF and ROHOUSOVA, "Species-specific antigens in salivary glands of phlebotomine sandflies," <i>Parasitology</i> , 122:37-41, 2001.
/NA/		VOLF <i>et al.</i> , "Salivary proteins and glycoproteins in phlebotomine sandflies of various species, sex and age," <i>Medical and Veterinary Entomology</i> , 14:251-256, 2000.
/NA/		Supplementary Partial European Search Report issued on February 21, 2006, for European Patent Application No. 03759395.1.

<b>EXAMINER SIGNATURE:</b>  / Nina Archie/	<b>DATE CONSIDERED:</b>  09/26/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

9.07.07

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Attorney Docket Number</b>	4239-66903-02
		<b>Application Number</b>	10/527,500
		<b>Filing Date</b>	March 11, 2005
		<b>First Named Inventor</b>	Valenzuela
		<b>Art Unit</b>	1645
		<b>Examiner Name</b>	Nina Archie
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>	
/NA/		Accession No. ABG18028, 18 Feb 2002, 1 page	

<b>EXAMINER SIGNATURE:</b>	/Nina Archie/	<b>DATE CONSIDERED:</b>	09/26/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Attorney Docket Number</b>	4239-66903-02
		<b>Application Number</b>	10/527,500
		<b>Filing Date</b>	March 11, 2005
		<b>First Named Inventor</b>	Valenzuela
		<b>Art Unit</b>	1645
		<b>Examiner Name</b>	Nina Archie
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>	
/NA/		Accession No. ABG18028, 18 Feb 2002, 1 page	

<b>EXAMINER SIGNATURE:</b>	/Nina Archie/	<b>DATE CONSIDERED:</b>	10/01/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			